Exclusive Summary

• The innovator patent has long expired, posing zero IP barriers and allowing for immediate, risk-free commercialization and distribution to address frequent regional supply shortages.
• Access to massive patient populations, including 1.28 billion global hypertension patients (as add-on therapy), millions of BPH patients, and soaring off-label demand for PTSD-associated nightmares.
• The 1mg dosage is the mandatory starting titration dose required by clinical guidelines to prevent first-dose syncope, making it the most frequently prescribed and essential SKU.
• Leveraging China's robust manufacturing scale and cost efficiency, the product offers highly competitive pricing, ensuring lucrative profit margins for overseas distributors.